Avantor Welcomes Jerry Porreca as New Executive Vice President for Quality and Regulatory

Avantor, Inc. (NYSE: AVTR), recognized globally for supplying crucial products and services in the life sciences and advanced technology sectors, has recently appointed Gerard (Jerry) Porreca as their new Executive Vice President of Quality and Regulatory. This strategic move underlines Avantor’s unwavering dedication to uphold the highest standards of quality and regulatory compliance across its operations.

In his capacity, Porreca will spearhead quality assurance initiatives, manage quality systems, and oversee regulatory affairs on a global scale. This role is vital for Avantor, considering its extensive scope of providing critical products and services that significantly influence the scientific sector.

Porreca arrives at Avantor boasting a wealth of experience in quality and regulatory affairs, especially within the life sciences, medical technology, and healthcare realms. He most recently played an instrumental role at Getinge, where he guided the Quality and Regulatory organization in navigating complex product approvals and engaging with regulatory bodies globally. During his tenure at Getinge, he successfully executed transformation initiatives that were essential for compliance across various regions, including the U.S., EU MDR, and China.

Prior to his time at Getinge, Porreca held senior executive positions at notable companies, including Becton Dickinson and Company, C.R. Bard, Inc., and Smith+Nephew plc. His comprehensive understanding of the regulatory landscape, coupled with a proven track record of enhancing quality systems, renders him an invaluable asset to Avantor as it continues to improve its operations.

Emmanuel Ligner, Avantor's President and CEO, expressed enthusiasm about Porreca joining the team, stating, "Delivering solutions that meet the highest standards of quality and reliability makes Avantor a trusted partner at every stage of the scientific journey. Jerry's deep expertise in global quality systems and complex regulatory landscapes will be vital as we continue to enhance and scale our operations and deliver mission-critical solutions for our customers." Ligner’s remarks emphasize the pivotal role quality plays in Avantor’s commitment to its clientele.

In response to his new role, Porreca remarked, "In the life sciences and advanced technology sectors, quality and regulatory excellence are not just requirements—they are a key value proposition for our customers. I look forward to working with our global teams to further strengthen our quality systems and leverage data-driven insights to help our customers accelerate the delivery of life-changing breakthroughs to patients worldwide." This statement reflects his forward-thinking approach, highlighting his intention to utilize insights and qualitative improvements as catalysts for customer success.

As Avantor strives to maintain its reputation as a leading life science tools company, this appointment is not only timely but crucial. Porreca’s leadership is anticipated to bolster Avantor's position as a trusted collaborator for scientific advancements. The company remains committed to providing a wide array of mission-critical products and services crucial for various phases of research and production across more than 300,000 customer locations in 180 countries.

With this strategic appointment, Avantor reinforces its pledge to deliver superior quality and regulatory adherence, key elements in facilitating groundbreaking developments in medicine, healthcare, and technology. The expertise that Porreca brings is set to be a cornerstone in Avantor’s ongoing journey to empower scientific breakthroughs that truly matter.

For additional insights about Avantor and its offerings, interested parties can visit the company's website at avantorsciences.com and follow them on their social media platforms, including LinkedIn, X (Twitter), and Facebook.